Fig. 1.

Survival and weight profile of Coxsackievirus B3 (CVB3)-infected mice treated with or without α-galactosylceramide (α-GalCer). BALB/c mice were infected with CVB3 to induce myocarditis as described in Materials and methods. α-GalCer or vehicle control were administered via intraperitoneal injection at the same time of viral challenge (a,b). In the treatment protocol, α-GalCer were administered daily from day 3 to day 8 (c,d). Mouse body weight (a,c) and survival (b,d) were scored and monitored daily. Each group consisted of five to seven mice. Data are representative of three independent experiments.